Alex Wei
About Alex Wei
Alex Wei is a scientist specializing in CRISPR platforms at Mammoth Biosciences, where he has worked since 2023. He holds a PhD in Neuroscience from the University of Pennsylvania and has a strong background in community outreach and gene-editing technologies.
Work at Mammoth Biosciences
Alex Wei currently serves as a Scientist in CRISPR Platforms at Mammoth Biosciences, a position he has held since 2023. He is based in Brisbane, California, where he contributes to the development and application of CRISPR technologies. His role involves leveraging his expertise in gene-editing to advance the company's initiatives in biotechnology.
Education and Expertise
Alex Wei earned a Doctor of Philosophy (PhD) in Neuroscience from the University of Pennsylvania School of Medicine, completing his studies from 2016 to 2022. He also holds a Bachelor of Science (BS) in Biopsychology from UC Santa Barbara, which he obtained from 2011 to 2015. His educational background provides a strong foundation in neuroscience and gene-editing technologies.
Background
Before his current role, Alex Wei worked at the University of Pennsylvania as a Neuroscience PhD Candidate from 2016 to 2023. He also served as a Graduate Teaching Assistant at the same institution for five months in 2018. Additionally, he worked as a Healthcare Consultant with Penn Biotech Group in 2020. Earlier in his career, he was a Research Associate at UC Santa Barbara from 2014 to 2016.
Achievements
Alex Wei has published scientific papers in the field of functional epigenomics, highlighting his contributions to the academic community. He possesses skills in quantitative DNA modification profiling, which is essential for analyzing genetic changes. His experience includes extensive work in federal funding acquisition for scientific research projects, demonstrating his capability in securing resources for innovative research.
Community Outreach and Passion
Alex Wei has a strong commitment to community outreach, particularly in educating the public about gene-editing technologies. He is passionate about integrating gene therapy and gene-editing technologies with translational therapeutics, aiming to bridge the gap between scientific research and practical applications in healthcare.